Buscar
Mostrando ítems 11-20 de 23
Protein stabilization by RSUME accounts for PTTG pituitary tumor abundance and oncogenicity
(BioScientifica, 2018-06)
Increased levels of the proto-oncogene pituitary tumor-transforming gene 1 (PTTG) have been repeatedly reported in several human solid tumors, especially in endocrine-related tumors such as pituitary adenomas. Securin PTTG ...
Endocan, VEGF, FGF2 and PDGF Expression in Pituitary Tumors: A Precise Angiogenic Marker Relationship in the Context of Tumor Invasiveness
(Editors Advisory Group, 2021-01-20)
Background: Pituitary adenomas can become invasive and aggressive, and in turn produce tumor recurrence. Endocan or endothelial cell specific molecule-1 (ESM1) has been associated with angiogenesis and tumor growth in ...
Autocrine IL-6 mediates pituitary tumor senescence
(Impact Journals LLC, 2017-01)
Cellular senescence is a stable proliferative arrest state. Pituitary adenomas are frequent and mostly benign, but the mechanism for this remains unknown. IL-6 is involved in pituitary tumor progression and is produced by ...
Igf-1 gene therapy as a potentially useful therapy for spontaneous prolactinomas in senile rats
(Bentham Science Publishers, 2018-08)
Background: Insulin-like Growth Factor1 (IGF1) is a powerful neuroprotective molecule. We have previously shown that short-term hypothalamic IGF1 gene therapy restores tuberoinfundibu-lar dopaminergic neuron function in ...
T3 receptors in human pituitary tumors
(Maney Publishing, 2013-12-02)
Objective: The purpose of this work was to investigate the synthesis of T3 receptors in human tumors of the anterior pituitary gland, its relationship with the hormone synthesized and/or secreted by the tumor and the ...
Effect of SOM230 (Pasireotide) on corticotropic cells: Action in dogs with Cushing's disease
(Karger, 2011-09)
SOM230 (pasireotide) is a multiligand somatostatin (SRIF) analog able to bind to somatostatin receptor (SSTR) subtypes 1, 2, 3 and 5, and trigger antisecretory and antiproliferative signaling cascades. Canines have become ...
Translational research in pituitary tumours
(BioScientifica, 2019-12)
Although effective treatment regimens (surgical resection, drug treatment with dopamine agonists or somatostatin analogues, radiotherapy) have been established for the therapy of most pituitary tumours, a considerable ...
Dopaminergic D2 receptor knockout mouse: an animal model of prolactinoma
(Karger, 2006)
Dopamine receptor type 2 (D2R) knockout mice (KO) have chronic hyperprolactinemia, pituitary hyperplasia, and a moderate decrease in MSH content. They are also growth retarded evidencing an alteration in the GH-IGF-I axis. ...
Pivotal role of NF-κB in cellular senescence of experimental pituitary tumours
(BioScientifica, 2020-05)
The molecular mechanisms underlying the capability of pituitary tumours to avoid unregulated cell proliferation are still not well understood. However, the NF-κB transcription factor, which is able to modulate not only ...
The pituitary TGFb1 system as a novel target for the treatment of resistant prolactinomas
(BioScientifica, 2016-03)
Prolactinomas are the most frequently observed pituitary adenomas and most of themrespond well to conventional treatment with dopamine agonists (DAs). However, a subsetof prolactinomas fails to respond to such therapies ...